Transparent leadership

Dylan Hallerberg is a seasoned private equity and investment executive with extensive experience operating and improving businesses. He started his career in investment banking at Moelis & Company, after which he worked at The Carlyle Group from 2010 to 2017, where he invested in European public and private markets. Following Carlyle, Mr. Hallerberg continued his investment career as an Analyst/PM at GoldenTree Asset Management before transitioning to leadership roles at Arcturus UAV and Fortress Marine Anchors. He has extensive board experience, having served on seven boards as a member, observer, or an executive. Dylan Hallerberg currently serves as the President and Owner of Fortress Marine Anchors and is an active real estate and private equity investor and family office advisor. He graduated Summa Cum Laude with Highest Honors from University of California, Santa Barbara with a degree in Business Economics. 
Dylan Hallerberg holds 150 000 shares in Photocure. He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. He is Chairperson of the Compensation Committee and Member of the Audit Committee.

Malene Brondberg served as interim CEO of Nordic Nanovector until 1 February 2023. She joined that company as Vice President Investor Relations in February 2018 and was appointed CFO in May 2020. She has over 20 years' operational experience in the financial services sector from a career that included being Global Head of Research and a member of the Executive Committee of the Nordic investment bank ABG Sundal Collier. Ms. Brondberg has also worked as a management consultant within the healthcare and financial sector and has acted as an advisor on investor relations and company funding. In addition, she has held interim CEO, COO and Head of Compliance / HR / Finance management positions at several companies. Malene Brondberg holds a Master of Science degree from Aalborg university in Denmark.
Malene Brondberg holds no shares in Photocure. She is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. She is Chairperson of the Audit Committee.

Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years. Her industry career spans over 30 years, during which she held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation. She is founder and CEO of Kupando GmbH. She was chairperson of Amal Therapeutics. Dr. Holldack has a medical degree from Georg-August-University in Göttingen, Germany and is a board certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School. 
Johanna Holldack holds no shares and 804 share options in Photocure. She is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. She is Member of the Compensation Committee and Member of the Scientific Committee.

Dr. Shore is Medical Director for the Carolina Urologic Research Center and is a Fellow of the American College of Surgeons. He has conducted more than 400 clinical trials focusing mainly on genitourinary oncology. Dr. Shore performs peer reviews for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and other high-impact scientific journals. He serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network (BCAN). He has served as the National/Global Urology Research Director for GenesisCare from 2019-2023. From 2016 to 2018 Dr. Shore was the President of the Large Urology Group Practice Association. In addition, he has served on  numerous Committees, Editorial and Review boards, such as the AUA Research and Innovations Committees, Health and Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and the World Journal of Urology. Neal Shore holds no shares and 804 share options in Photocure.
He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. He is Chairperson of the Scientific Committee & Advisor for ESG matters.